Literature DB >> 319750

Therapy of murine aspergillosis with amphotericin B in combination with rifampin of 5-fluorocytosine.

J Arroyo, G Medoff, G S Kobayashi.   

Abstract

Suboptimal doses of amphotericin B in combination with either rifampin or 5-fluorocytosine were better than single-drug therapy in the treatment of disseminated Aspergillus fumigatus infection in mice. Despite the increased effectiveness of combination therapy, none of the therapeutic regimens we used completely eradicated infections in the mice when evaluated by mycological culture, even in long-term survivors.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 319750      PMCID： PMC351911          DOI： 10.1128/AAC.11.1.21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  OCULAR PENETRATION OF AMPHOTERICIN B: A REPORT OF LABORATORY STUDIES AND A CASE REPORT OF POSTSURGICAL CEPHALOSPORIUM ENDOPHTHALMITIS.

Authors:  W R GREEN; J E BENNETT; R D GOOS
Journal:  Arch Ophthalmol       Date:  1965-06

2.  Depression of phagocytosis by solutes in concentrations found in the kidney and urine.

Authors:  I CHERNEW; A I BRAUDE
Journal:  J Clin Invest       Date:  1962-10       Impact factor: 14.808

3.  The combined effect of 5-fluorocytosine and amphotericin B in the therapy of murine cryptococcosis.

Authors:  E R Block; J E Bennett
Journal:  Proc Soc Exp Biol Med       Date:  1973-02

4.  Conditions for immunosuppression by rifampicin.

Authors:  L Bassi; L Di Berardino; V Arioli; L G Silvestri; E L Lignière
Journal:  J Infect Dis       Date:  1973-12       Impact factor: 5.226

5.  Activity of amphotericin B, 5-fluorocytosine, and rifampin against six clinical isolates of Aspergillus.

Authors:  M Kitahara; V K Seth; G Medoff; G S Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

6.  Chemotherapeutic activity of 5-fluorocytosine and amphotericin B against Candida albicans in mice.

Authors:  E Titsworth; E Grunberg
Journal:  Antimicrob Agents Chemother       Date:  1973-09       Impact factor: 5.191

7.  Factors determining the susceptibility of mice to experimental phycomycosis.

Authors:  M J Corbel; S M Eades
Journal:  J Med Microbiol       Date:  1975-11       Impact factor: 2.472

8.  Amphotericin B potentiation of rifampicin as an antifungal agent against the yeast phase of Histoplasma capsulatum.

Authors:  G S Kobbayashi; G Medoff; D Schlessinger; C N Kwan; W E Musser
Journal:  Science       Date:  1972-08-25       Impact factor: 47.728

9.  Potentiation of rifampicin and 5-fluorocytosine as antifungal antibiotics by amphotericin B (yeast-membrane permeability-ribosomal RNA-eukaryotic cell-synergism).

Authors:  G Medoff; G S Kobayashi; C N Kwan; D Schlessinger; P Venkov
Journal:  Proc Natl Acad Sci U S A       Date:  1972-01       Impact factor: 11.205

10.  Potentiation of the antifungal effects of antibiotics by amphotericin B.

Authors:  C N Kwan; G Medoff; G S Kobayashi; D Schlessinger; H J Raskas
Journal:  Antimicrob Agents Chemother       Date:  1972-08       Impact factor: 5.191
View more
  23 in total

Review 1.  Antifungal activity of nonantifungal drugs.

Authors:  J Afeltra; P E Verweij
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-06-26       Impact factor: 3.267

2.  In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents.

Authors:  Eric Dannaoui; Javier Afeltra; Jacques F G M Meis; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 3.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

Review 4.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

Review 5.  Host immune defense against Aspergillus fumigatus: insight from experimental systemic (disseminated) infection.

Authors:  I Mirkov; S Stosic-Grujicic; M Kataranovski
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

6.  Efficacy and pharmacodynamics of flucytosine monotherapy in a nonneutropenic murine model of invasive aspergillosis.

Authors:  D T A te Dorsthorst; P E Verweij; J F G M Meis; J W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

7.  In vitro activities of amphotericin B in combination with four antifungal agents and rifampin against Aspergillus spp.

Authors:  C E Hughes; C Harris; J A Moody; L R Peterson; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

8.  Efficacy of intravenous itraconazole against experimental pulmonary aspergillosis.

Authors:  H M Miyazaki; S Kohno; Y Miyazaki; K Mitsutake; K Tomono; M Kaku; H Koga; K Hara
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

Review 9.  Aspergillosis of the CNS in a pediatric liver transplant recipient: case report and review.

Authors:  M Green; E R Wald; A Tzakis; S Todo; T E Starzl
Journal:  Rev Infect Dis       Date:  1991 Jul-Aug

10.  Effects of antifungal agent combinations administered simultaneously and sequentially against Aspergillus fumigatus.

Authors:  S Maesaki; S Kohno; M Kaku; H Koga; K Hara
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.